Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases

8 Pages Posted: 18 Apr 2023

See all articles by Daniel Tobias Michaeli

Daniel Tobias Michaeli

Heidelberg University - National Center for Tumor Diseases

Thomas Michaeli

Heidelberg University - Department of Personalized Oncology

Date Written: April 17, 2023

Abstract

This cross-sectional study compares Medicare & Medicaid spending on and beneficiaries of ultra-rare, rare, common, and non-orphan cancer drugs.


Funding/Support: No funding was received for conducting this study. T.M. was supported by the DKFZ clinician-scientist program. D.T.M. was supported by the Federal Ministry of Education and Research (BMBF) Young Scientist Award the German Cancer Society’s (DKG) Young Talent Award, and by the German Research Foundation (DFG) Travel Grant.

Note:
Funding Information: No funding was received for conducting this study.

Conflict of Interests: The authors declare that they have no conflicts of interest.

Keywords: orphan designation, cancer drug, healthcare expenditure, rare orphans, ultra-rare orphans, common orphans, rare diseases

JEL Classification: I1, I10, I13, I18

Suggested Citation

Michaeli, Daniel Tobias and Michaeli, Thomas, Spending on Orphan Cancer Drugs for Ultra-Rare, Rare, and Common Diseases (April 17, 2023). Available at SSRN: https://ssrn.com/abstract=4421181 or http://dx.doi.org/10.2139/ssrn.4421181

Daniel Tobias Michaeli (Contact Author)

Heidelberg University - National Center for Tumor Diseases ( email )

Germany

Thomas Michaeli

Heidelberg University - Department of Personalized Oncology ( email )

0 References

    0 Citations

      Do you have a job opening that you would like to promote on SSRN?

      Paper statistics

      Downloads
      85
      Abstract Views
      531
      Rank
      609,458
      PlumX Metrics
      Plum Print visual indicator of research metrics
      • Usage
        • Abstract Views: 479
        • Downloads: 77
      • Captures
        • Readers: 1
      see details